Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update
03 nov. 2016 16h13 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Cempra to Present Solithromycin at FDA Antimicrobial Drugs Advisory Committee Meeting on November 4, 2016
30 août 2016 09h15 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra’s Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases
25 août 2016 16h05 HE
|
Cempra, Inc.
— Both pivotal Phase 3 studies now published in leading infectious disease journals — — FDA and EMA currently reviewing marketing applications for solithromycin for CABP in U.S. and EU — CHAPEL...
Cempra Appoints Dr. David Zaccardelli to Board of Directors
11 août 2016 16h05 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces FDA Acceptance of Solithera™ New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia
05 juil. 2016 07h00 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., July 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference
10 juin 2016 07h30 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., June 10, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at the Jefferies 2016 Healthcare Conference
02 juin 2016 08h00 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., June 02, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)
25 mai 2016 16h30 HE
|
Melinta Therapeutics, Inc.
Solithromycin safety and efficacy further validated by Toyama (FUJIFILM) All efficacy outcome measures favored solithromycin Management to host Q&A webcast and conference call tomorrow at 8:00...
Cempra to Present at the Needham and Company 15th Annual Healthcare Conference
06 avr. 2016 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
24 févr. 2016 16h05 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics in the face of rising antibiotic resistant...